GeneDx Holdings Corp

WGS is in a Stage 2 advancing regime with a clear Higher Highs & Higher Lows pattern. Price recently tested and was rejected at the declining 200-day SMA, and is now pulling back into rising 9- and 20-day EMAs. The medium-term bias remains bullish, but short-term timing is neutral—awaiting acceptance above the EMAs before entering. Deferred entry (Stalk) into shallow pullbacks offers a better risk/reward setup.

• ↑Q2 revenue $114.4M (+32% YoY) with 30K+ tests conducted
• ↑Payer coverage jumped from 47% to 87%, improving reimbursement
• ↓Q1 2026 adjusted net loss of $8.2M raises viability concerns